Maen, AbdelrahimGök Yavuz, BetülMohamed, Yehia I.Esmail, AbdullahLu, JianmingMohamed, AmrAzmi, Asfar S.Kaseb, MohamedKasseb, OsamaLi, DanGocio, MichelleKoçak, MehmetSelim, AbdelhafezMa, QingKaseb, Ahmed O.2024-03-062024-03-062024Maen, A., Gök Yavuz, B., Mohamed, Y. I., Esmail, A., Lu, J., Mohamed, A. ... Kaseb, A. O. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology, 15. https://dx.doi.org/10.3389/fphar.2024.12912121663-9812https://dx.doi.org/10.3389/fphar.2024.1291212https://hdl.handle.net/20.500.12511/12340Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.enAttribution 4.0 Internationalinfo:eu-repo/semantics/openAccessCOVID-19Thymoquinone TQCoronavirusCOVID-19 and Anti-Viral AgentsTQ FormulaFatty AcidsArticle1510.3389/fphar.2024.1291212Q10011646325000012-s2.0-8518531668838379905Q1